<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Volatility on FinanClub</title>
    <link>https://finan.club/tags/volatility/</link>
    <description>Recent content in Volatility on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 20 Feb 2024 09:06:18 +0000</lastBuildDate><atom:link href="https://finan.club/tags/volatility/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>PLUG</title>
      <link>https://finan.club/us/plug/</link>
      <pubDate>Tue, 20 Feb 2024 09:06:18 +0000</pubDate>
      
      <guid>https://finan.club/us/plug/</guid>
      <description>score:160
Chances: Plug Power Inc. announced a comprehensive initiative to significantly reduce its annual operational expenses by more than $75 million, which could enhance its financial performance and ensure long-term value creation in a competitive market. The company delivered first-of-its-kind portable refuelers to transit agencies and trucking fleet customers, removing a significant barrier to the consideration of fuel cell electric vehicles.</description>
    </item>
    
    <item>
      <title>OWL</title>
      <link>https://finan.club/us/owl/</link>
      <pubDate>Thu, 18 Jan 2024 09:06:03 +0000</pubDate>
      
      <guid>https://finan.club/us/owl/</guid>
      <description>score:46
Chances: Blue Owl Capital Inc. and Blue Owl Capital Corporation are both scheduled to release their financial results for the fourth quarter, providing potential opportunities for investors to assess the performance of these companies. Risks: The volatility of the stock market and potential fluctuations in the financial performance of Blue Owl Capital Inc.</description>
    </item>
    
    <item>
      <title>MRNA</title>
      <link>https://finan.club/us/mrna/</link>
      <pubDate>Wed, 17 Jan 2024 09:04:41 +0000</pubDate>
      
      <guid>https://finan.club/us/mrna/</guid>
      <description>score:-55
Chances: Moderna&amp;rsquo;s product pipeline includes a wide range of modalities, such as prophylactic vaccines, cancer vaccines, and localized regenerative therapeutics, providing opportunities for significant future growth. The company&amp;rsquo;s focus on intratumoral immuno-oncology and systemic intracellular therapeutics reflects a strong commitment to addressing complex medical challenges with innovative solutions.</description>
    </item>
    
  </channel>
</rss>
